EMA Authorised: Inrebic (fedratinib dihydrochloride monohydrate) — Bristol Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA authorises Inrebic (fedratinib dihydrochloride monohydrate) for myeloproliferative disorders, including primary myelofibrosis, with Bristol Myers Squibb…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Disorders

Drugs mentioned

• INREBIC (fedratinib hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Myeloproliferative Disorders;Primary Myelofibrosis. MAH: Bristol Myers Squibb Pharma EEIG. Decision date: 23/06/2026. Orphan medicine